PLEASANTON, CA--(MARKET WIRE)--Aug 22, 2006 -- Biotech business leader Howard D. Goldstein has accepted the top position at Arcxis Biotechnologies, signaling the company's move into commercial development of its technologies for rapid, diagnostic gene and protein identification. As president and chief executive officer, Mr. Goldstein will commence hiring and operational changes needed to effect the company's transition from R&D to commercial product development, use his extensive experience in the pharmaceutical and biotech industries to accelerate product beta-test and applications development programs, and guide the company's commercial product introductions.
Mr. Goldstein is well known among business leaders in the San Francisco Bay Area's corporate biotech community and venture capital groups specializing in biotech investments. Prior to joining Arcxis, Mr. Goldstein provided strategic product commercialization and financing guidance to a number of biotech instrumentation companies. Mr. Goldstein has held executive-level positions at Amnis Corporation, Argonaut Technologies, Incyte Genomics, Molecular Devices, and Molecular Dynamics, and was chief executive officer of Entigen Corporation. Since 1979, Mr. Goldstein has specialized in the market for laboratory instrumentation, software, reagents, and consumable products.
"The technologies developed at Arcxis are perfect for the research and diagnostic markets because they work so easily, quickly and economically," said Mr. Goldstein. "The user's perspective was considered from the very beginning, and the resulting systems are simple to operate and compatible with automation. I'm impressed and pleased to be moving forward with the support of the Arcxis team and the capital community."
Arcxis Biotechnologies is a maker of laboratory systems for disease pathogen detection and clinical diagnostics. Headquarters are in Pleasanton, California. For additional information, please call (925) 461-1300 or visit www.arcxis.com.
Howard D. Goldstein
President & CEO
Arcxis Biotechnologies Inc.
Source: Arcxis Biotechnologies
>>> Discuss This Story